Clinical Trial Update: DT-168 in Keratoplasty Patients With Fuchs Endothelial Corneal Dystrophy [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating DT-168 in keratoplasty patients with Fuchs Endothelial Corneal Dystrophy is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Fuchs Endothelial Corneal Dystrophy

Drugs mentioned

• DT-168 (DT-168)

Snippet

Sponsor: Design Therapeutics, Inc. | Conditions: Fuchs Endothelial Corneal Dystrophy, Fuchs | Phase 2 | Status: RECRUITING